|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Williet N, Petrillo A, Roth G, Ghidni M,
Petrova M, Forestier J, Lopez A, Thoor A, Weislinger L, De Vita F,
et al: Gemcitabine/nab-paclitaxel versus FOLFIRINOX in locally
advanced pancreatic cancer: A European multicenter study. Cancers
(Basel). 13:27972021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Geus SWL, Eskander MF, Kasumova GG, Ng
SC, Kent TS, Mancias JD, Callery MP, Mahadevan A and Tseng JF:
Stereotactic body radiotherapy for unresected pancreatic cancer: A
nationwide review. Cancer. 123:4158–4167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krishnan S, Chadha AS, Suh Y, Chen HC, Rao
A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, et al:
Focal radiation therapy dose escalation improves overall survival
in locally advanced pancreatic cancer patients receiving induction
chemotherapy and consolidative chemoradiation. Int J Radiat Oncol
Biol Phys. 94:755–765. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shinoto M, Terashima K, Suefuji H,
Matsunobu A, Toyama S, Fukunishi K and Shinoyama Y: A single
institutional experience of combined carbon-ion radiotherapy and
chemotherapy for unresectable locally advanced pancreatic cancer.
Radiother Oncol. 129:333–339. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsuda T, Ajiki W, Marugame T, Ioka A,
Tsukuma H and Sobue T; Research Group of Population-Based Cancer
Registries of Japan, : Population-based survival of cancer patients
diagnosed between 1993 and 1999 in Japan: A chronological and
international comparative study. Jpn J Clin Oncol. 41:40–51. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: the unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bilimoria KY, Bentrem DJ, Ko CY, Stewart
AK, Winchester DP and Talamonti MS: National failure to operate on
early stage pancreatic cancer. Ann Surg. 246:173–180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Doi R, Imamura M, Hosotani R, Imaizumi T,
Hatori T, Takasaki K, Funakoshi A, Wakasugi H, Asano T, Hishinuma
S, et al: Surgery versus radiochemotherapy for resectable locally
invasive pancreatic cancer: final results of a randomized
multi-institutional trial. Surg Today. 38:1021–1028. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sultana A, Tudur Smith C, Cunningham D,
Starling N, Tait D, Neoptolemos JP and Ghaneh P: Systematic review,
including meta-analyses, on the management of locally advanced
pancreatic cancer using radiation/combined modality therapy. Br J
Cancer. 96:1183–1190. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vandercappellen J, Van Damme J and Struyf
S: The role of CXC chemokines and their receptors in cancer. Cancer
Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kulbe H, Levinson NR, Balkwill F and
Wilson JL: The chemokine network in cancer-much more than directing
cell movement. Int J Dev Biol. 48:489–496. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng Y, Broder CC, Kennedy PE and Berger
EA: Pillars article: HIV-1 entry cofactor: functional cDNA cloning
of a seven-transmembrane, G protein-coupled receptor. Science.
1996.272:872–877, J Immunol 186. 6076–6081. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chatterjee S, Behnam Azad B and Nimmagadda
S: The intricate role of CXCR4 in cancer. Adv Cancer Res.
124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zlotnik A: New insights on the role of
CXCR4 in cancer metastasis. J Pathol. 215:211–213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Liu C, Mo X, Shi H and Li S:
Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in
pancreatic cancer. Oncol Lett. 15:1771–1776. 2018.PubMed/NCBI
|
|
20
|
Krieg A, Riemer JC, Telan LA, Gabbert HE
and Knoefel WT: CXCR4-a prognostic and clinicopathological
biomarker for pancreatic ductal adenocarcinoma: A meta-analysis.
PLoS One. 10:e01301922015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui K, Zhao W, Wang C, Wang A, Zhang B,
Zhou W, Yu J, Sun Z and Li S: The CXCR4-CXCL12 pathway facilitates
the progression of pancreatic cancer via induction of angiogenesis
and lymphangiogenesis. J Surg Res. 171:143–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sleightholm RL, Neilsen BK, Li J, Steele
MM, Singh RK, Hollingsworth MA and Oupicky D: Emerging roles of the
CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.
Pharmacol Ther. 179:158–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Clercq E: The bicyclam AMD3100 story.
Nat Rev Drug Discov. 2:581–587. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Skerlj RT, Bridger GJ, Kaller A, McEachern
EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, et
al: Discovery of novel small molecule orally bioavailable C-X-C
chemokine receptor 4 antagonists that are potent inhibitors of
T-tropic (X4) HIV-1 replication. J Med Chem. 53:3376–3388. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cabioglu N, Summy J, Miller C, Parikh NU,
Sahin AA, Tuzlali S, Pumiglia K, Gallick GE and Price JE:
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu
in breast cancer cells by a novel pathway involving Src kinase
activation. Cancer Res. 65:6493–6497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hartmann TN, Burger JA, Glodek A, Fujii N
and Burger M: CXCR4 chemokine receptor and integrin signaling
co-operate in mediating adhesion and chemoresistance in small cell
lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ohira S, Sasaki M, Harada K, Sato Y, Zen
Y, Isse K, Kozaka K, Ishikawa A, Oda K, Nimura Y and Nakanuma Y:
Possible regulation of migration of intrahepatic cholangiocarcinoma
cells by interaction of CXCR4 expressed in carcinoma cells with
tumor necrosis factor-alpha and stromal-derived factor-1 released
in stroma. Am J Pathol. 168:1155–1168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yasumoto K, Koizumi K, Kawashima A, Saitoh
Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi
Y, et al: Role of the CXCL12/CXCR4 axis in peritoneal
carcinomatosis of gastric cancer. Cancer Res. 66:2181–2187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marchesi F, Monti P, Leone BE, Zerbi A,
Vecchi A, Piemonti L, Mantovani A and Allavena P: Increased
survival, proliferation, and migration in metastatic human
pancreatic tumor cells expressing functional CXCR4. Cancer Res.
64:8420–8427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saur D, Seidler B, Schneider G, Algül H,
Beck R, Senekowitsch-Schmidtke R, Schwaiger M and Schmid RM: CXCR4
expression increases liver and lung metastasis in a mouse model of
pancreatic cancer. Gastroenterology. 129:1237–1250. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bockorny B, Semenisty V, Macarulla T,
Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ,
Pedersen KS, et al: BL-8040, a CXCR4 antagonist, in combination
with pembrolizumab and chemotherapy for pancreatic cancer: the
COMBAT trial. Nat Med. 26:878–885. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morimoto M, Matsuo Y, Koide S, Tsuboi K,
Shamoto T, Sato T, Saito K, Takahashi H and Takeyama H: Enhancement
of the CXCL12/CXCR4 axis due to acquisition of gemcitabine
resistance in pancreatic cancer: Effect of CXCR4 antagonists. BMC
Cancer. 16:3052016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang JT, Chan SH, Lin CY, Lin TY, Wang
HM, Liao CT, Wang TH, Lee LY and Cheng AJ: Differentially expressed
genes in radioresistant nasopharyngeal cancer cells: gp96 and
GDF15. Mol Cancer Ther. 6:2271–2279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Matsuyama A, Inoue H, Shibuta K, Tanaka Y,
Barnard GF, Sugimachi K and Mori M: Hepatoma-derived growth factor
is associated with reduced sensitivity to irradiation in esophageal
cancer. Cancer Res. 61:5714–5717. 2001.PubMed/NCBI
|
|
35
|
Fukuda K, Sakakura C, Miyagawa K, Kuriu Y,
Kin S, Nakase Y, Hagiwara A, Mitsufuji S, Okazaki Y, Hayashizaki Y
and Yamagishi H: Differential gene expression profiles of
radioresistant oesophageal cancer cell lines established by
continuous fractionated irradiation. Br J Cancer. 91:1543–1550.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang T, Tamae D, LeBon T, Shively JE, Yen
Y and Li JJ: The role of peroxiredoxin II in radiation-resistant
MCF-7 breast cancer cells. Cancer Res. 65:10338–10346. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu QY, Gao Y, Liu Y, Yang WZ and Xu XY:
Identification of differential gene expression profiles of
radioresistant lung cancer cell line established by fractionated
ionizing radiation in vitro. Chin Med J (Engl). 121:1830–1837.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bustin SA: Quantification of mRNA using
real-time reverse transcription PCR (RT-PCR): Trends and problems.
J Mol Endocrinol. 29:23–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sasaki K, Natsugoe S, Ishigami S,
Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K,
Sakurai T, et al: Expression of CXCL12 and its receptor CXCR4
correlates with lymph node metastasis in submucosal esophageal
cancer. J Surg Oncol. 97:433–438. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Taichman RS, Cooper C, Keller ET, Pienta
KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived
factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
|
|
41
|
Luther SA, Bidgol A, Hargreaves DC,
Schmidt A, Xu Y, Paniyadi J, Matloubian M and Cyster JG: Differing
activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in
lymphocyte and dendritic cell recruitment and lymphoid neogenesis.
J Immunol. 169:424–433. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Billadeau DD, Chatterjee S, Bramati P,
Sreekumar R, Shah V, Hedin K and Urrutia R: Characterization of the
CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest
Cancer. 37:110–119. 2006.PubMed/NCBI
|
|
43
|
Zlotnik A: Chemokines in neoplastic
progression. Semin Cancer Biol. 14:181–185. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kucia M, Jankowski K, Reca R, Wysoczynski
M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J and Ratajczak MZ:
CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol
Histol. 35:233–245. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vaz AP, Ponnusamy MP, Seshacharyulu P and
Batra SK: A concise review on the current understanding of
pancreatic cancer stem cells. J Cancer Stem Cell Res. 2:e10042014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Maréchal R, Demetter P, Nagy N, Berton A,
Decaestecker C, Polus M, Closset J, Devière J, Salmon I and Van
Laethem JL: High expression of CXCR4 may predict poor survival in
resected pancreatic adenocarcinoma. Br J Cancer. 100:1444–1451.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Singh S, Srivastava SK, Bhardwaj A, Owen
LB and Singh AP: CXCL12-CXCR4 signalling axis confers gemcitabine
resistance to pancreatic cancer cells: a novel target for therapy.
Br J Cancer. 103:1671–1679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang D, Jiao C, Zhu Y, Liang D, Zao M,
Meng X, Gao J, He Y, Liu W, Zhong Z and Cheng Z: Activation of
CXCL12/CXCR4 renders colorectal cancer cells less sensitive to
radiotherapy via up-regulating the expression of survivin. Exp Biol
Med (Maywood). 242:429–435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Oweida A, Phan A, Vancourt B, Robin T,
Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, et al:
Hypofractionated radiotherapy is superior to conventional
fractionation in an orthotopic model of anaplastic thyroid cancer.
Thyroid. 28:739–747. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim JY, Kim HJ, Jung CW, Lee TS, Kim EH
and Park MJ: CXCR4 uses STAT3-mediated slug expression to maintain
radioresistance of non-small cell lung cancer cells: Emerges as a
potential prognostic biomarker for lung cancer. Cell Death Dis.
12:482021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mahadevan D and Von Hoff DD: Tumor-stroma
interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther.
6:1186–1197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Neesse A, Algül H, Tuveson DA and Gress
TM: Stromal biology and therapy in pancreatic cancer: A changing
paradigm. Gut. 64:1476–1484. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Santagata S, Ieranò C, Trotta AM,
Capiluongo A, Auletta F, Guardascione G and Scala S: CXCR4 and
CXCR7 signaling pathways: A focus on the cross-talk between cancer
cells and tumor microenvironment. Front Oncol. 11:5913862021.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li D, Qu C, Ning Z, Wang H, Zang K, Zhuang
L, Chen L, Wang P and Meng Z: Radiation promotes
epithelial-to-mesenchymal transition and invasion of pancreatic
cancer cell by activating carcinoma-associated fibroblasts. Am J
Cancer Res. 6:2192–2206. 2016.PubMed/NCBI
|
|
57
|
Mosi RM, Anastassova V, Cox J, Darkes MC,
Idzan SR, Labrecque J, Lau G, Nelson KL, Patel K, Santucci Z, et
al: The molecular pharmacology of AMD11070: An orally bioavailable
CXCR4 HIV entry inhibitor. Biochem Pharmacol. 83:472–479. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dale DC, Firkin F, Bolyard AA, Kelley M,
Makaryan V, Gorelick K, Ebrahim T, Garg V, Tang W, Jiang H, et al:
Results of a phase 2 trial of an oral CXCR4 antagonist,
mavorixafor, for treatment of WHIM syndrome. Blood. 136:2994–3003.
2020. View Article : Google Scholar : PubMed/NCBI
|
